Bristol Myers Squibb: new data for Breyanzy
(CercleFinance.com) - Bristol Myers Squibb has announced the results of the primary analysis of the pivotal TRANSCEND CLL 004 study, a single-arm, open-label, multicentre, phase 1/2 study evaluating Breyanzi in adult patients with relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL).
Results showed that Breyanzi achieved statistically significant complete response rates, the primary endpoint of the study, in 18.4% of patients in the primary efficacy analysis set.
Amongst patients who achieved a complete response, there was no disease progression or death, and the median duration of response was not reached.
The data will be the subject of an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) on 6 June.
Copyright (c) 2023 CercleFinance.com. All rights reserved.
Results showed that Breyanzi achieved statistically significant complete response rates, the primary endpoint of the study, in 18.4% of patients in the primary efficacy analysis set.
Amongst patients who achieved a complete response, there was no disease progression or death, and the median duration of response was not reached.
The data will be the subject of an oral presentation at the annual meeting of the American Society of Clinical Oncology (ASCO) on 6 June.
Copyright (c) 2023 CercleFinance.com. All rights reserved.